Individualising care – considerations in the escalation of pharmacological management of type 2 diabetes - ACRRM


2 hrs



# of Credits




Expiry Date


Attaining optimal blood glucose management in patients with type 2 diabetes is important to improve both short-term and long-term health outcomes. A sustained legacy effect of intensive glucose-management in type 2 diabetes has been observed, indicating a continued reduction in microvascular risk. In addition, the legacy effect demonstrates an association between intensive glucose management and a significantly decreased risk of myocardial infarction and death.

A general glycaemic target of HbA1c = 7% (53mmol/mol) has therefore been recommended for newly diagnosed and uncomplicated patients. Over 60% of patients, however, are reported as not achieving their glycaemic goals. One Australian study showed less than half of patients with type 2 diabetes seen in general practice had an HbA1c = 7% (53 mmol/mol) with 25% having an HbA1c > 8% (64mmol/mol). Current glycaemic management seems to be “missing the target” of accepted treatment goals.

This online CME event is an Accredited Distance/Remote based education module as defined by the Professional Development Program of the Australian College of Rural and Remote Medicine. ACRRM member participation and information will be noted and sent directly to the ACRRM for accreditation processing. Please allow 30 days for ACRRM to send you your points. This activity is approved for 2.00 Core Point(s).


John Eric Barlow
Clinical Supervisor, University of Notre Dame, NSW
Surgical Assistant Strathfield Private Hospital, NSW
Westmead Private Hospital, NSW

Rachel Freeman
APD, CDE, BHSc (Nut&Diet), MSc (Diabetes)
Professional Services Manager
Australian Diabetes Educators Association


Related Courses